Genmab Announces Share Capital Increase
Company Announcement
Genmab A/S (Nasdaq: GMAB) has increased its share capital by 11,729 shares following the exercise of employee warrants. The step reinforces Genmab’s approach to sharing value creation with its people and encouraging broad-based equity ownership across the company.
Details of the Capital Increase
The new shares are issued without preemption rights—so existing shareholders do not have priority to buy these shares before issuance. The capital increase comes from cash subscriptions at different prices, reflecting solid participation from employees who chose to exercise their warrants. The subscriptions were completed at the following prices:
- 4,623 shares at DKK 1,025.00
- 3,656 shares at DKK 1,032.00
- 561 shares at DKK 1,050.00
- 1,645 shares at DKK 1,334.50
- 1,015 shares at DKK 1,432.00
- 229 shares at DKK 1,615.00
Gross proceeds from these exercises total approximately DKK 13.1 million. Following the issue, Genmab’s total share capital will be DKK 66,176,831, corresponding to 66,176,831 ordinary shares. All shares carry equal voting power, preserving one-share, one-vote alignment across the shareholder base.
Implications for Shareholders and Next Steps
The newly issued shares amount to roughly 0.02% of Genmab’s total share capital. By supporting employee participation through warrant exercises, Genmab aims to align long-term incentives while staying focused on innovation in biopharmaceuticals. The new shares carry the same rights as existing ordinary shares, including voting rights and dividends. They are expected to be admitted to trading and official listing on Nasdaq Copenhagen after registration with the Danish Business Authority.
About Genmab and Its Mission
Founded in 1999, Genmab is a biotechnology company dedicated to developing antibody therapeutics. Its work is centered on improving patient outcomes with therapies that aim to go beyond standard treatment options. The pipeline includes, among other modalities, bispecific T-cell engagers and immune checkpoint modulators. Genmab’s 2030 vision looks to advance care for cancer and other serious diseases and to deliver what the company describes as ‘knock-your-socks-off’ (KYSO®) antibody medicines.
Headquartered in Copenhagen and active across North America, Europe, and the Asia Pacific, Genmab continues to invest in science and development to meet significant medical needs. For more information on the company and its latest updates, visit Genmab.com.
Contact Information:Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
Frequently Asked Questions
Why did Genmab increase its share capital?
The increase stems from employees exercising their warrants. It reflects both employee confidence in Genmab’s outlook and the company’s commitment to employee ownership.
How much capital was raised through the warrant exercises?
The exercises generated gross proceeds of approximately DKK 13.1 million through cash subscriptions at various prices.
Do existing shareholders have preemption rights for these new shares?
No. The new shares were issued without preemption rights, meaning existing shareholders did not have priority to buy them before they were issued.
How large is the new issuance relative to Genmab’s total share capital?
The 11,729 newly issued shares represent about 0.02% of the company’s total share capital. All new shares have the same rights as existing ordinary shares, including voting and dividend rights.
What happens next with the newly issued shares?
After registration with the Danish Business Authority, the new shares are expected to be admitted to trading and official listing on Nasdaq Copenhagen, on the same terms as Genmab’s existing ordinary shares.
